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Abstract
Objective—To determine the impact of RAS mutation status on survival and patterns of
recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after
preoperative modern chemotherapy.
Summary Background Data—RAS mutation has been reported to be associated with
aggressive tumor biology. However, the effect of RAS mutation on survival and patterns of
recurrence after resection of CLM remains unclear.
Methods—Somatic mutations were analyzed using mass spectroscopy in 193 patients who
underwent single-regimen modern chemotherapy before resection of CLM. The relationship
between RAS mutation status and survival outcomes was investigated.
Results—Detected somatic mutations included RAS (KRAS/NRAS) in 34 patients (18%),
PIK3CA in 13 (7%), and BRAF in 2 (1%). At a median follow-up of 33 months, 3-year overall
survival (OS) rates were 81% in patients with wild-type vs 52.2% in patients with mutant RAS
(P=0.002); 3-year recurrence-free survival (RFS) rates were 33.5% with wild-type vs 13.5% with
mutant RAS (P=0.001). Liver and lung recurrences were observed in 89 and 83 patients,
respectively. Patients with RAS mutation had a lower 3-year lung RFS rate (34.6% vs 59.3%,
P<0.001), but not a lower 3-year liver RFS rate (43.8% vs 50.2%, P=0.181). In multivariate
Correspondence and reprints: Jean-Nicolas Vauthey, MD, Department of Surgical Oncology, The University of Texas MD
Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX 77030, Phone: (713) 792-2022, Fax: (713) 745-1921,
jvauthey@mdanderson.org.
*Dr. Vauthey and Dr. Zimmitti contributed equally.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflicts of Interest The authors report no conflicts of interest relevant to this article.
NIH Public Access
Author Manuscript
Ann Surg. Author manuscript; available in PMC 2014 October 01.
Published in final edited form as:
Ann Surg. 2013 October ; 258(4): . doi:10.1097/SLA.0b013e3182a5025a.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
analyses, RAS mutation predicted worse OS (hazard ratio [HR] 2.3, P=0.002), overall RFS (HR
1.9, P=0.005), and lung RFS (HR 2.0, P=0.01), but not liver RFS (P=0.181).
Conclusions—RAS mutation predicts early lung recurrence and worse survival after curative
resection of CLM. This information may be used to individualize systemic and local tumor-
directed therapies and follow-up strategies.
INTRODUCTION
For patients with colorectal liver metastases (CLM), hepatic resection combined with
systemic therapy has been reported to be the most effective treatment in terms of improving
survival.[1] To date, various prognostic scoring systems have been proposed to stratify
patient prognosis after resection of CLM.[2–4] However, in the era of modern systemic
therapy, these conventional scoring systems are becoming less relevant because of
inconsistent predictive power and lack of reproducibility due to selection bias.[5]
Preoperative systemic therapy has increasingly been used as part of a multidisciplinary
approach for patients with CLM to test the biologic aggressiveness of the tumor and select
optimal candidates for surgery.[6] Our group has reported that pathologic response[7–9] and
radiologic response[10, 11] to preoperative chemotherapy are powerful predictors of long-
term outcomes for patients with CLM. However, in patients with CLM, there is strong
variability in clinical presentation, biologic aggressiveness, and patterns of treatment failure,
and no biomarker predicts these phenotypic differences.
During the past decade, mutation status of RAS family genes (predominantly KRAS and
NRAS) has been shown to correlate with the effectiveness of anti-EGFR agents against
unresectable metastatic colorectal cancer,[12, 13] and a possible prognostic role of these
somatic gene mutations after resection of CLM in an era predating the use of preoperative
chemotherapy has been reported.[14] Our group has recently reported that metachronous
CLM detected after modern chemotherapy for the primary colorectal tumor are associated
with a higher incidence of somatic gene mutations and worse survival.[15] In addition, while
recently reported studies have indicated a per-patient concordance of mutation type between
primary tumor and metastases, a higher rate of mutation has been identified in patients with
metastases at particular sites (e.g., peritoneum, lung and brain metastases), suggesting that
tumors with mutations have a propensity to metastasize to the lungs and brain.[16–19]
On the basis of these clinical findings, we hypothesized that somatic mutation status predicts
survival outcomes and types of recurrence after curative resection of CLM. In this study, we
investigated the impact of RAS mutation status on survival and patterns of recurrence in
patients who underwent curative resection of CLM after preoperative modern chemotherapy.
PATIENTS AND METHODS
Study Population
The Institutional Review Board of The University of Texas MD Anderson Cancer Center
approved this study protocol (PA11-0653). The prospectively maintained liver resections
database of the Department of Surgical Oncology was queried to identify all patients who
underwent liver resection for CLM during the period from November 1997 through October
2011. We studied patients undergoing curative hepatectomy without concomitant
radiofrequency ablation. Patients with a history of previous treatment for metastatic disease
(chemotherapy, radiofrequency ablation, or resection) were excluded.
All patients included in this study received preoperative oxaliplatin- or irinotecan-based
chemotherapy including the anti-VEGF agent bevacizumab. Patients who received anti-
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EGFR agents were excluded. Patients who received 2 or more regimens of preoperative
chemotherapy because of disease progression during first-line chemotherapy were excluded
from the current study, as were patients who died within 90 days after hepatectomy and
patients who had less than 5% viable tumor cells in the CLM specimen.
Preoperative, Intraoperative, and Postoperative Management
Before operation, all patients underwent a medical history, physical examination, laboratory
evaluation, and imaging studies, including helical computed tomography of the chest,
abdomen, and pelvis with a triphasic liver protocol. In selected patients, fluorodeoxyglucose
positron emission tomography was used to rule out extrahepatic disease and confirm the
metastatic nature of atypical lesions. Only patients with hepatic and extrahepatic disease
amenable to complete and safe resection were considered for hepatectomy. In patients with
an anticipated insufficient future liver remnant, preoperative portal vein embolization was
used to induce hypertrophy.
During laparotomy, intraoperative sonography of the liver was performed to confirm the
location of known CLM and their relation to the portal pedicles or the hepatic veins and to
rule out the presence of previously undetected CLM. Parenchymal transection was carried
out under total or selective hepatic inflow occlusion using the Cavitron Ultrasonic Surgical
Aspirator (Valleylab, Boulder, CO) and saline-linked cautery (dissecting sealer DS 3.0,
Tissuelink Medical, Inc, Dover, NH) as reported previously.[20]
All specimens were subjected to histologic evaluation to confirm the diagnosis of metastatic
colorectal cancer and determine the width of the tumor-free surgical margin. The degree of
pathologic response of CLM to preoperative chemotherapy was defined according to the
percentage of the CLM tumor surface area composed of viable tumor cells: major pathologic
response was defined < 50% viable cells and minor pathologic response ≥ 50% viable
cells.[7] After surgery, chemotherapy was usually reintroduced to complete a total of 12
cycles including both preoperative and postoperative chemotherapy. Patients were
reassessed every 4 months after completion of the second stage of liver resection.
Radiological evidence or positive biopsy was required to confirm recurrence, and time and
site of relapse were systematically recorded. Further treatment was decided according to the
findings at reassessment.
DNA Extraction and Somatic Gene Mutation Profiling
Hematoxylin-eosin-stained slides from all CLM were reviewed by a gastrointestinal
pathologist (DMM). Tumor viability in the CLM specimens was checked in order to exclude
specimens with tumor viability less than 5%. Areas with maximum amount of available
tumor were selected for macrodissection. Tumor tissue was scraped from the glass slides
under direct visualization or under a dissecting microscope, and DNA was extracted from
tumor tissue using a QIAmp DNA Mini Kit (Qiagen, Valencia, CA).
Somatic gene mutations were assessed using mass spectrometry. DNA extracted from
formalin-fixed, paraffin-embedded resected CLM was quantified and analyzed with
Sequenom MassARRAY technology (Sequenom, Inc., San Diego, CA).[21] Sequenom’s
MassARRAY system utilizes polymerase chain reaction amplification and single-base
primer extension for mutation detection.[22–24] The MassARRAY system offers a highly
effective method for profiling hundreds of somatic mutations in parallel. A high-throughput
analysis of 159 point mutations in 33 genes commonly involved in solid tumors was
performed in MD Anderson’s Characterized Cell Line Core Facility. The genes tested for
this study were AKT1, AKT2, AKT3, ALK, BRAF, CDK4, CTNNB1, DEAR1, EGFR, ERA,
FRAP, GNAS, HIF1A, IDH1, IDH2, IGFR1R, JAK2, KIT, KRAS, MEK1, MET, NRAS,
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PDGFRA, PDPK1, PHLPP2, PIK3CA, PIK3R1, PRKAG1, PRKAG2, RET, RICTOR,
STK11, and TNK2.
Statistical Analysis
Qualitative variables were expressed as frequencies. Patients were stratified according to
KRAS or NRAS mutation status into 2 groups: mutant RAS and wild-type RAS.
Clinicopathological features were compared between these 2 groups using chi-square or
Fisher’s exact tests, as appropriate. Overall survival (OS), overall recurrence-free survival
(RFS), lung RFS, and liver RFS were calculated using the Kaplan–Meier method from the
date of liver resection to the date of death, first recurrence at any site, lung recurrence, or
liver recurrence, respectively. Patients without an event during the follow-up period were
censored at the date of last follow-up. These survival outcomes were compared using the
log-rank test.
To identify factors associated with OS and RFS in the entire study cohort, we evaluated the
following clinicopathologic variables in a univariate analysis: disease-free interval after the
primary tumor diagnosis (<12 months vs ≥12 months), primary tumor location (rectum vs
colon), regional lymph node status of the primary tumor (positive vs negative), RAS
mutation status (mutant vs wild-type), number of cycles of preoperative chemotherapy for
CLM (>6 vs ≤6), pathologic response to preoperative chemotherapy (major vs minor),
number of CLM in the pathologic specimen (multiple vs solitary), diameter of the largest of
the CLM in the pathologic specimen (>5 vs ≤5 cm), major postoperative complications were
defined as complications of grade 3 or higher (necessitating a surgical, endoscopic or
radiological procedure) in the Dindo classification[25], and liver resection margin status on
microscopic analysis (positive vs negative),.
All variables associated with OS, overall RFS, lung RFS, and liver RFS with P<0.1 in the
univariate proportional hazards models were entered into a Cox multivariate regression
model with backward elimination. P<0.05 was considered statistically significant. Statistical
analyses were performed using the software IBM SPSS Statistics, version 19 (IBM,
Armonk, NY).
RESULTS
Among 1406 consecutive patients treated for CLM at MD Anderson during the study period,
621 were excluded because of concomitant radiofrequency ablation or nonreceipt of
preoperative chemotherapy. An additional 497 patients were excluded because they received
multiple lines of preoperative chemotherapy, did not receive bevacizumab, received anti-
EGFR agents before or after liver resection, had less than 5% viable tumor cells in the
specimen, died within 90 days after surgery, or underwent a noncurative hepatectomy.
Among the 288 patients eligible for the genetic testing, 95 patients were excluded because
they did not have available paraffin blocks or had insufficient DNA for genetic analysis. The
remaining 193 patients were studied in detail (Figure 1).
Somatic Gene Mutation Status
Of the 193 patients included in the study, 43 (22.3%) had one or more somatic mutations in
tested genes. Thirty-four patients (17.6%) had RAS mutations (27 KRAS and 7 NRAS), 13
patients (6.7%) had PIK3CA mutations, 2 patients (1%) had BRAF mutations, and 2 patients
(1%) had rare mutations—one had a CTNNB1 mutation, and the other had an AKT1
mutation. Among the 34 patients with RAS mutations, 29 (85%) exhibited a mutation at
codon 12 (nucleotide changes: G→A in 17 patients, G→T in 8 patients, and G→C in 4
patients), 3 (9%) exhibited a mutation at codon 61 (A→G in 1 patient, A→C in 1 patient,
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and C→G in 1 patient), and 2 (6%) exhibited a mutation at codon 13 (G→A in both of
them). Among the 13 patients with PIK3CA mutations, 6 (46%) exhibited a mutation at
codon 20 and 7 (54%) at codon 9.
Patient Characteristics by RAS Mutation Status
Clinicopathologic characteristics by RAS mutation status are shown in Table 1. Patients with
RAS mutation had a lower rate of major pathologic response (< 50% viable tumor cells) than
patients with wild-type RAS (38.2% vs 58.5%; P=0.037). The remaining characteristics did
not differ significantly between patients with mutant and wild-type RAS.
Long-term Survival and Predictors of Outcomes
At a median follow-up time of 33 months, 51 patients had died (48 of cancer and 3 of other
causes), 54 were alive with disease recurrence, and 88 were alive with no evidence of
disease at last follow-up. For the entire cohort, 3- and 5-year RFS rates were 29.9% and
26.9%, respectively, and 3- and 5-year OS rates were 76.4% and 61.8%, respectively.
Patients with mutant RAS had worse long-term outcomes than those with wild-type RAS (3-
year RFS: 13.5% vs 33.5%, P=0.001; 3-year OS: 52.2% vs 81%, P=0.002) (Figure 3).
In multivariate analysis, independent risk factors of worse RFS were RAS mutation (hazard
ratio [HR], 1.9; 95% CI, 1.2–3.0; P=0.005) and minor pathologic response to preoperative
chemotherapy (HR, 2.0; 95% CI, 1.4–3.0; P<0.001) (Table 2). Independent risk factors of
worse OS also were RAS mutation (HR, 2.3; 95% CI, 1.1–4.5; P=0.002) and minor
pathologic response (HR, 2.1; 95% CI, 1.1–4.0; P=0.022) (Table 3).
Patterns of Recurrence and Predictors of Recurrence Pattern
Of the 126 patients who had tumor recurrence during the follow-up period, 83 patients had a
lung recurrence and 89 patients had a liver recurrence. Patients with mutant RAS had worse
3-year lung-RFS than those with wild-type RAS (34.6% vs 59.3%, P<0.001) (Figure 4A,
Table 4). In contrast, 3-year liver-RFS was not influenced by RAS mutation (43.8% for
mutant RAS vs 50.2% for wild-type RAS, P=0.181) (Figure 4B, table 4). At the last follow-
up, lung recurrence was observed in 64.7% of patients with RAS mutation (22/34) versus
38.3% of patients with wild-type RAS (61/159) (P=0.005). The incidence of liver recurrence
did not correlate significantly with RAS mutation status (44.7% of patients with RAS
mutation vs 52.9% of those with wild-type RAS; P=0.379).
Multivariate analysis indicated that RAS mutation (HR, 2.0; 95% CI, 1.1–3.4; P=0.01) and
minor pathologic response (HR, 1.9; 95% CI, 1.1–3.0; P=0.009) were independent
predictors of lung RFS, while minor pathologic response was the only independent predictor
of liver RFS (HR, 2.2; 95% CI, 1.4–3.5; P=0.001) (Tables 4 and 5).
DISCUSSION
In this study, we analyzed the prognostic impact of RAS mutation status in 193 patients who
underwent curative resection of CLM after single-regimen modern systemic therapy.
Consistent with previous oncogene profiling studies for primary colorectal cancers, RAS,
BRAF, and PIK3CA were identified as the most common point-mutated genes in
CLM.[23, 26] Our analysis indicates that RAS mutation status is an independent predictor of
OS, overall RFS, and lung RFS, but not liver RFS after resection of CLM. The current study
also confirms our previous study indicating the pre-eminence of response to chemotherapy
as a dynamic biological predictor outcome superior to traditional clinical pathological
predictors such as number of liver metastases, size of liver metastases, lymph node status of
primary tumor or surgical margins.[7, 27] Over the past decade, the prognostic role of
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somatic mutations has been actively investigated, especially in primary colorectal cancer.
The most common somatic gene mutations reported in previous studies were KRAS, NRAS,
PIK3CA, and BRAF, with mutation rates around 40%, 2.6%, 14.5%, and 4.7%,
respectively.[13] The previous studies of molecular alterations in colorectal cancer included
patients with advanced and unresectable metastatic disease. The current study indicates that
KRAS mutation rates are lower in patients selected to undergo curative resection of CLM
than in medical series reporting on KRAS mutation in patients with advanced metastatic
colorectal cancer not amenable to curative resection. This suggests that among patients
affected by metastatic colorectal cancer, those amenable to curative resection of CLM
represent a preselected population with better tumor biology and longer survival. This
hypothesis is supported by the fact that the only study reporting on rates of KRAS mutations
indicated a 25% rate of mutations in patients undergoing resection after receiving
preoperative modern chemotherapy.[28]
In this study, we analyzed the mutation status of multiple somatic genes and found that of 43
patients with at least one somatic gene mutation, the majority had a RAS mutation (n=34),
while only a small minority had mutations of PIK3CA (n=5), BRAF (n=2), CTTNB1 (n=1),
and AKT1 (n=1). This finding confirms the dominance of RAS mutations in colorectal cancer
and suggests that the less common mutations (of PIK3CA, BRAF, CTTNB1, and AKT1) are
unlikely to contribute significantly to future overall outcome analyses of patients undergoing
resection of CLM. However, it is still possible that, in future studies, these rare mutations
could help to predict outcomes of specific subsets of patients with poor prognosis or specific
metastatic patterns.
Only a few prior studies[16–18] have focused on mutation rates and recurrence patterns in
patients with colorectal cancer. Tie et al[16] reported higher rates of RAS mutations in
colorectal lung metastases than in CLM. In the current study, we specifically looked at
patterns of recurrence following hepatectomy. The results indicate that, compared to wild-
type RAS, RAS mutation is associated with a shorter 3-year lung RFS rate (34.6% vs 59.3%,
P<0.001), but not with a shorter liver RFS rate (43.8% vs 50.2%, P=0.181) (Figure 4).
These results suggest a propensity for RAS-mutated tumors to metastasize to lungs and are in
line with the results of previous studies that have shown higher KRAS mutation rates in lung
(62%) and brain (57%) metastases from colorectal cancer than in CLM (32%).[16, 17] This
discordance in mutation rates suggests the possibility that KRAS-mutant tumors are
biologically versatile and able to grow in different visceral organs and have higher capacity
for systemic vascular (as opposed to portal vascular) tumor spread. These findings argue in
favor of studying molecular heterogeneity and differences in biologic interaction between
colon cancer tumor cells and host organ factors at different metastatic sites, in in vitro and in
vivo models, comparing KRAS-mutant and KRAS-wild-type colorectal cancer.
In a previous study, indeterminate lung nodules were reported in 43% of patients undergoing
chest computed tomography before resection of CLM. Only 35% of indeterminate nodules
proved to be lung metastases, and their presence was not associated with worse survival,
leading the authors to conclude that the presence of indeterminate lung nodules should not
preclude resection of CLM.[29] The findings from our current study, while supporting the
role of preoperative chest computed tomography before resection of CLM, suggest that
nonspecific lung nodules in patients with RAS mutations may be more likely to represent
metastatic disease. This information may help physicians select, among patients with
multiple and bilobar CLM requiring extensive resection, those who may benefit from an
aggressive surgical approach. In addition, our data favor the use of chest computed
tomography surveillance after resection of CLM in patients harboring a RAS mutation.
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The RAS mutation rate in the current study (18%) is lower than the 47% RAS mutation rate
reported in our previous study in patients undergoing resection of metachronous CLM.[15]
We interpret the findings of our previous study as indicating that adjuvant chemotherapy for
6 months after resection of the primary tumor resulted in a selection pressure favoring the
onset of metachronous liver metastases enriched for KRAS mutations and prevented
metastases in a number of patients with primary tumors with wild-type KRAS - similar to the
phenomenon by which antibiotic therapy can select for treatment-resistant bacteria. These
interpretations are consistent with findings from other studies indicating that adjuvant
FOLFOX for the primary tumor does not cause mutations in CLM.[30, 31] and that the
mutation types remain concordant between the primary tumor and CLM in more than 90%
of patients when the primary and the metastases are compared.[32–36]
In contrast with our previous study, our current work focused on patients who underwent
single-regimen preoperative modern chemotherapy for 2–3 months and excluded patients
who had received multiple lines of chemotherapy. Therefore, the current study focused on a
clinically preselected population of patients with favorable tumor biology accounting for the
low mutation rate. In addition, the analysis of clinical and pathological differences between
patients with mutant RAS and those with wild-type RAS indicated similar median numbers of
chemotherapy cycles in the two groups (Table 1). This data supports the concept that
preoperative chemotherapy for liver metastases does not affect the RAS mutation rate.[37]
Taken together, these mutational data do not argue against the use of modern chemotherapy
as adjuvant therapy for primary tumors or neoadjuvant therapy for liver metastases.
The limitations of this study include its retrospective nature and the selected patient
population due to limited availability of specimens suitable for genetic analysis. However,
the present analysis was based on a patient population with similar pathologic and clinical
characteristics, and RAS mutation status well stratified patients with respect to prognosis and
patterns of recurrence, even after exclusion of patients with very good pathologic response
to chemotherapy (% of residual tumor cells < 5%), in whom genetic profiling was
impossible due to very low proportion of residual viable tumor cells in the specimen and
consequent insufficient DNA for genetic analysis.
In conclusion, RAS mutation status is a powerful predictor of OS, RFS, and lung recurrence
after curative resection of CLM. These data indicate that the genetic profile of CLM can be
used to improve selection of patients with CLM for surgery and predict outcome of patients
with CLM. In addition, the finding of a higher rate of pathologic response in patients with
wild-type RAS sets the stage for further studies focusing on somatic gene mutations and
pattern of response associated with preoperative chemotherapy.
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FIGURE 1.
Selection of study population.
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FIGURE 2.
Somatic gene mutations.
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FIGURE 3.
Overall survival (OS) (A) and recurrence-free survival (RFS) (B) according to RAS mutation
status.
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FIGURE 4.
Lung (A) and liver (B) recurrence-free survival (RFS) according to RAS mutation status.
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Table 1
Clinicopathologic Characteristics by RAS Mutation Status
Characteristic Wild-type
RAS
(n=159)
MutantRAS
(n=34)
Univariate
Analysis
P Value
Disease-free interval <12 months, no. (%) (n=130) 107 (67.3) 23 (67.6) 0.968
Rectal primary tumor, no. (%) (n=39) 32 (20.1) 7 (20.6) 0.951
Primary tumor positive nodal status, no. (%) (n=133) 107 (67.3) 26 (76.5) 0.294
No. of cycles of preoperative chemotherapy, median (range) 6 (2–23) 6 (3–24) 0.345
% viable tumor cells <50%, no. (%) (n=106) 93 (58.5) 13 (38.2) 0.037
No. of CLM, median (range) 2 (1–80) 3 (1–18) 0.569
Diameter of largest of CLM, mm, median (range) 25 (5–150) 22.5 (5–100) 0.484
CLM indicates colorectal liver metastases.
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Table 4
Univariate and Multivariate Analysis of Factors Associated with Lung Recurrence after Resection of CLM
Factor
3-year Lung
RFS (%)
Univariate
Analysis
P Value
Multivariate Analysis
P
Value Hazard Ratio (95% CI)
Disease-free intervala
  <12 months (n=130) 52.7 0.680
  ≥12 months (n=63) 59.7
Primary tumor location
  Rectum (n=39) 34.3 0.016 0.069
  Colon (n=154) 59.4
Primary tumor nodal status
  Positive (n=133) 52.8 0.511
  Negative (n=60) 59.7
RAS mutation status
  Mutant (n=34) 34.6 <0.001 0.01 2.01 (1.20 – 3.41)
  Wild-type (n=159) 59.3
No. of cycles of preoperative chemotherapy
  >6 (n=65) 54.6 0.976
  ≤6 (n=128) 55.9
Pathologic response
  %VTC ≥50% (n=87) 39.7 0.001 0.009 1.91 (1.17 – 3.10)
  %VTC <50% (n=106) 64.5
No. of CLM
  Multiple (n=125) 50.3 0.062 NS
  Single (n=68) 66
Diameter of largest of CLM
  >5 cm (n=24) 45.5 0.04 NS
  ≥5 cm (n=169) 56.4
Major complication
  Yes (n=32) 34.2 0.164
  No (n=161) 57.7
Surgical margin
  Positive (n=19) 81.3 0.295
  Negative (n=174) 73.1
CLM indicates colorectal liver metastases; NS, not significant; RFS, recurrence-free survival; %VTC, percentage viable tumor cells.
a
From diagnosis of primary tumor to diagnosis of CLM.
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Table 5
Univariate and Multivariate Analysis of Factors Associated with Liver Recurrence after Resection of CLM
Factor
3-year Liver
RFS (%)
Univariate
Analysis
P Value
Multivariate Analysis
P Value Hazard Ratio (95% CI)
Disease-free intervala
  <12 months (n=130) 45 0.016 NS
  ≥12 months (n=63) 58.4
Primary tumor location
  Rectum (n=39) 44.3 0.533
  Colon (n=154) 50.3
Primary tumor nodal status
  Positive (n=133) 42.3 0.018 0.072 1.64 (0.96 – 2.83)
  Negative (n=60) 64.6
RAS mutation status
  Wild-type (n=159) 43.8 0.181
  Mutant (n=34) 50.2
No. of cycles of preoperative chemotherapy
  >6 (n=65) 43.2 0.164
  ≤6 (n=128) 52.6
Pathologic response
  %VTC ≥50% (n=87) 33.1 <0.001 0.001 2.22 (1.41 – 3.52)
  %VTC <50% (n=106) 58.8
No. of CLM
  Multiple (n=125) 42.1 0.015 NS
  Single (n=68) 63.9
Diameter of largest of CLM
  >5 cm (n=24) 35.1 0.127
  ≥5 cm (n=169) 51.2
Major complication
  Yes (n=32) 37.1 0.066
  No (n=161) 51.7
Surgical margin
  Positive (n=19) 38.2 0.402
  Negative (n=174) 49.1
CLM indicates colorectal liver metastases; NS, not significant; RFS, recurrence-free survival; %VTC, percentage viable tumor cells.
a
From diagnosis of primary tumor to diagnosis of CLM.
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